TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate. Hernández-Mitre, M. P., Morpeth, S. C., Venkatesh, B., Hills, T. E., Davis, J., Mahar, R. K., McPhee, G., Jones, M., Totterdell, J., Tong, S. Y., & Roberts, J. A. Clinical Microbiology and Infection, 30(6):743–754, June, 2024.
TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate [link]Paper  doi  bibtex   
@article{hernandez-mitre_tmprss2_2024,
	title = {{TMPRSS2} inhibitors for the treatment of {COVID}-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate},
	volume = {30},
	issn = {1198743X},
	shorttitle = {{TMPRSS2} inhibitors for the treatment of {COVID}-19 in adults},
	url = {https://linkinghub.elsevier.com/retrieve/pii/S1198743X24000557},
	doi = {10.1016/j.cmi.2024.01.029},
	language = {en},
	number = {6},
	urldate = {2024-05-30},
	journal = {Clinical Microbiology and Infection},
	author = {Hernández-Mitre, María Patricia and Morpeth, Susan C. and Venkatesh, Balasubramanian and Hills, Thomas E. and Davis, Joshua and Mahar, Robert K. and McPhee, Grace and Jones, Mark and Totterdell, James and Tong, Steven Y.C. and Roberts, Jason A.},
	month = jun,
	year = {2024},
	pages = {743--754},
}

Downloads: 0